Unveiling the Renoprotective Mechanisms of Schisandrin B in Ischemia-Reperfusion Injury Through Transcriptomic and Pharmacological Analysis
Changhong Xu,Yun Deng,Jiangwei Man,Huabin Wang,Tuanjie Che,Liyun Ding,Li Yang
DOI: https://doi.org/10.2147/dddt.s489458
IF: 4.3188
2024-09-22
Drug Design Development and Therapy
Abstract:Changhong Xu, 1, &ast Yun Deng, 1, &ast Jiangwei Man, 1, &ast Huabin Wang, 1 Tuanjie Che, 2 Liyun Ding, 3 Li Yang 1 1 Department of Urology, Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, People's Republic of China; 2 Innovation Center of Functional Genomics and Molecular Diagnostics Technology of Gansu Province, Lanzhou, People's Republic of China; 3 School of Physical Science and Technology, Lanzhou University, Lanzhou, 730000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Yang, Department of Urology, Institute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, People's Republic of China, Email Objective: This study investigates the targets, pathways, and mechanisms of Schisandrin B (Sch B) in alleviating renal ischemia-reperfusion injury (RIRI) using RNA sequencing and network pharmacology. Methods: The effects of Sch B on RIRI were assessed using hematoxylin-eosin (HE) and periodic acid-Schiff (PAS) staining, along with measurements of blood creatinine and urea nitrogen (BUN). Differential gene expression in mouse models treated with RIRI and Sch B+RIRI was analyzed through RNA-Seq. Key processes, targets, and pathways were examined using network pharmacology techniques. The antioxidant capacity of Sch B was evaluated using assays for reactive oxygen species (ROS), mitochondrial superoxide, and JC-1 membrane potential. Molecular docking was employed to verify the interactions between key targets and Sch B, and the expression of these targets and pathway was confirmed using qRT-PCR, Western blot, and immunofluorescence. Results: Sch B pre-treatment significantly reduced renal pathological damage, inflammatory response, and apoptosis in a mouse RIRI model. Pathological damage scores dropped from 4.33 ± 0.33 in the I/R group to 2.17 ± 0.17 and 1.5 ± 0.22 in Sch B-treated groups (p < 0.01). Creatinine and BUN levels were also reduced (from 144.6 ± 21.05 μmol/L and 53.51 ± 2.34 mg/dL to 50.44 ± 5.61 μmol/L and 17.18 ± 0.96 mg/dL, p < 0.05). Transcriptomic analysis identified four key targets (AKT1, ALB, ACE, CCL5) and the PI3K/AKT pathway. Experimental validation confirmed Sch B modulated these targets, reducing apoptosis and oxidative stress, and enhancing renal recovery. Conclusion: Sch B reduces oxidative stress, inflammation, and apoptosis by modulating key targets such as AKT1, ALB, ACE, and CCL5, while activating the PI3K/AKT pathway, leading to improved renal recovery in RIRI. Keywords: renal ischemia-reperfusion injury, schisandrin B, transcriptomics, network pharmacology, PI3K/AKT pathway Renal ischemia-reperfusion injury (RIRI) is widely prevalent in clinical practice, particularly in scenarios such as kidney transplantation, acute kidney damage, and cardiovascular surgeries. The onset of this pathological state involves multiple complex mechanisms, including oxidative stress, inflammatory responses, and cellular apoptosis, 1 which are pivotal factors. Oxidative stress is a central factor, arising from the overproduction of reactive oxygen species (ROS) during reperfusion. These ROS damage cellular components, including lipids, proteins, and DNA, which leads to mitochondrial dysfunction and amplifies cellular injury. In addition, ROS act as signaling molecules, triggering inflammatory responses and apoptosis. 2 Inflammation is another key driver of RIRI, characterized by the activation and infiltration of immune cells, such as neutrophils and macrophages, into the renal tissue. The ischemic insult prompts the release of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, further promoting tissue damage and increasing oxidative stress. This creates a vicious cycle, where inflammation and oxidative stress exacerbate each other, ultimately contributing to renal dysfunction. 3 Furthermore, apoptosis plays a critical role in RIRI, particularly through mitochondrial and extrinsic pathways. The ischemic phase results in ATP depletion and cellular homeostasis disruption, while reperfusion triggers apoptotic signaling. Key regulators, including caspases and Bcl-2 family proteins, orchestrate the programmed cell death of renal tubular epithelial cells, leading to extensive cell loss and functional decline. 4 RIRI can lead to acute and chronic graft dysfunction in renal transplant recipients postoperatively, significantly impacting their prognosis. 2,5 Despite widesprea -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal